お知らせ • May 05
Pasithea Therapeutics Corp. Appoints Kartik Krishnan as Chief Medical Officer, Effective May 1, 2026 Pasithea Therapeutics Corp. announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (CMO) of the Company, effective May 1, 2026. Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neurofibromatosis type 1 (NF1) associated plexiform and cutaneous neurofibromas. Dr. Krishnan has over 20 years of experience in clinical development, pharmacovigilance, clinical operations, regulatory affairs, and R&D strategy. Prior to joining Pasithea, Dr. Krishnan was Chief Executive Officer at OncoNano Medicines, a privately held company developing anti-cancer assets. Prior to that, Dr. Krishnan was Chief Medical Officer at Arcus Biosciences, a discovery and clinical development company focusing on combination therapies in immuno-oncology. Earlier in his career, he held various clinical development and medical director roles of increasing responsibility at companies including, Astex Pharmaceuticals, Genentech, Five Prime Therapeutics, BioMarin, and Amgen. Prior to joining industry, Dr. Krishnan held a faculty position in the Department of Pediatrics at the University of Arizona, with both clinical and primary research responsibilities. While at Genentech, Dr. Krishnan was an integral part of the clinical team for cobimetanib (Cotellic), contributing to the approval in the United States and Europe in 2015, for treatment of BRAF V600E or BRAF V600K melanoma in combination with vemurafenib (Zelboraf). In addition, Dr. Krishnan worked to establish development opportunities for this MEK inhibitor beyond melanoma, including monotherapy work in diseases such as Langerhans cell histiocytosis (for which cobimetinib was approved in 2022) and novel combinations in breast and colon cancer. Dr. Krishnan received his B.A. in History (with Distinction) from the University of Virginia. He completed his M.D. and Ph.D. in Molecular, Biochemical and Biophysical Studies at Columbia University. His Ph.D. studies were completed in the lab of Dr. John Krolewski, focusing on JAK/STAT signaling in the interferon pathway. Dr. Krishnan trained in pediatrics at UCLA and in pediatric hematology and oncology at the Johns Hopkins University and the National Cancer Institute. お知らせ • Jul 16
Pasithea Therapeutics Corp., Annual General Meeting, Sep 03, 2025 Pasithea Therapeutics Corp., Annual General Meeting, Sep 03, 2025. お知らせ • Jun 11
Pasithea Therapeutics Appoints James Lee to Scientific Advisory Board Pasithea Therapeutics Corp. announced the appointment of Dr. James Lee to its scientific advisory board to help guide the development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis, and ankylosing spondylitis. Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other indications, and also identified that MEK inhibitors are the drug class that most effectively suppress ETS2-driven inflammation. Dr. James Lee is a Clinician Scientist Group Leader at the Francis Crick Institute (London, UK) and an Honorary Consultant Gastroenterologist at the Royal Free Hospital. He has clinical expertise in inflammatory bowel disease (IBD) and is also an active member of the UK and International IBD Genetics Consortia. Dr. Lee trained at Oxford, Cambridge, and Harvard and leads a research group that seeks to translate genetic associations into a better understanding of autoimmune and inflammatory disease biology. His research is internationally renowned with publications in such scientific journals as Nature and Cell. お知らせ • Sep 03
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board Pasithea Therapeutics Corp. announced that Rebecca Brown, M.D., Ph.D. has been appointed as a member of the Company’s Scientific Advisory Board. Dr. Brown is currently Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and Assistant Professor in the Department of Neurology (Division of Neuro-Oncology), Internal Medicine, and Neurosurgery at the institution. Dr. Brown will contribute scientific insights and valuable clinical perspectives to Pasithea's development of PAS-004. Dr. Brown has been an investigator in dozens of NF1 research studies including basic, translational, and clinical trials, with a focus on cutaneous and plexiform neurofibromas in NF1. Her research has been published extensively in major scientific journals and regularly serves as faculty at national and international meetings. Dr. Rebecca Brown (M.D., Ph.D.) is a board-certified adult neuro-oncologist who specializes in Neurofibromatosis (NF) and Schwannomatosis (SWN) genetic nerve tumor predisposition syndromes. She earned her Ph.D. from The University of Texas at Austin (UT Austin) in Neuroscience studying the molecular genomics and behavioral outcomes of endocrine-disrupting pollutants on females across multiple generations. Dr. Brown completed a post-doctoral fellowship at the Center for Strategic and Innovative Technologies at UT Austin in human performance research and then earned her M.D. from UT Southwestern in 2013. She completed her intern year at East Tennessee State University in 2014 and her neurology residency at Mount Sinai Hospital in NYC in 2017. She specialized in neuro-oncology during a fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) completed in 2019. She worked as an instructor at MSKCC for 18 months prior to accepting a position as Assistant Professor and Director of the all-ages NF and SWN Clinic at The Mount Sinai Health System in January 2021. Dr. Brown has experience on both sides of the bench in NF laboratory research involving the RAS-RAF-MEK-ERK (MAPK) pathway, including genome editing, cell culture, xenografts, and clinical trials. Her particular interest is in developing treatments for NF1-associated dermal tumors called cutaneous neurofibromas. お知らせ • May 17
Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024 Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024. Location: via the internet, United States お知らせ • Oct 27
Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023 Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023, at 09:00 US Eastern Standard Time. Agenda: To consider .Election of the director; to consider Adoption and approval of an amendment to Amended and Restated Certificate of Incorporation; to consider Approval of the Pasithea Therapeutics Corp. 2023 Stock Incentive Plan; to consider Adoption and approval of an Amended and Restated Certificate of Incorporation; to consider Ratification of the appointment of Marcum LLP as independent registered public accounting firm; to consider Transacting such other business as may properly come before the Annual Meeting or any adjournment thereof.